{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:38:59Z","timestamp":1783456739406,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-19-20174"],"award-info":[{"award-number":["ESR-19-20174"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>CKD is common in heart failure (HF) and associated with morbidity and mortality, yet life-prolonging medications such as renin-angiotensin-aldosterone inhibitors (RAASi) are underused due to risk of hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is a potassium-binding medication that has been shown to reduce incidence of hyperkalaemia in CKD, non-CKD, and HF populations, which we propose will support maximisation of RAASi therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We propose a 1:1 randomised, double-blind, placebo-controlled trial in which participants will receive either SZC or placebo. We will up-titrate participants\u2019 RAASi therapy while monitoring their serum potassium levels and adjusting their SZC dose if necessary. Participants with CKD and HF will be recruited from CKD and HF clinics at St George\u2019s Hospital. The total study period will be 18\u2009months; 130 participants will be enrolled for approximately two months each following screening. Our primary outcome will be the proportion of participants who achieve maximum RAASi dose while maintaining normokalaemia. Secondary outcomes include participants reaching maximum RAASi dose without severe hyperkalaemia; time from randomisation to hyperkalaemia; time from randomisation to severe hyperkalaemia; number of RAASi dose escalations per participant; final doses of RAASi therapy; changes in quality of life score, eGFR, ACR, serum sodium, troponin T; number and duration of hospital admissions; and within-participant change in serum potassium compared to baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial will be the first to examine the use of SZC for the maximisation of RAASi dosing in patients with advanced CKD and HF. We will assess the impact of achieving target RAASi dosing on hospital admission rates and duration of stay, with the hope that optimum RAASi treatment will translate into reduced morbidity and improved QoL. If clinical benefit is demonstrated, we hope that the joint multidisciplinary CKD-HF approach will be expanded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT number 2020\u2013002946-18. Registered on 08 June 2020. Online record pending.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02439-2","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T12:27:03Z","timestamp":1625574423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure"],"prefix":"10.1186","volume":"22","author":[{"given":"Daniel","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina Chis","family":"Ster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Carlos","family":"Kaski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-2325","authenticated-orcid":false,"given":"Debasish","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"issue":"7","key":"2439_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MAE, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014 Feb 1;35(7):455\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/eht386.","journal-title":"Eur Heart J"},{"issue":"6","key":"2439_CR2","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","volume":"95","author":"AA House","year":"2019","unstructured":"House AA, Wanner C, Sarnak MJ, Pi\u00f1a IL, McIntyre CW, Komenda P, et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019 Jun;95(6):1304\u201317. https:\/\/doi.org\/10.1016\/j.kint.2019.02.022.","journal-title":"Kidney Int"},{"issue":"1","key":"2439_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","volume":"167","author":"CB Bowling","year":"2013","unstructured":"Bowling CB, Sanders PW, Allman RM, Rogers WJ, Patel K, Aban IB, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD treatment trial. Int J Cardiol. 2013 Jul;167(1):151\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2011.12.056.","journal-title":"Int J Cardiol"},{"issue":"17","key":"2439_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jacc.2013.04.086","volume":"62","author":"R Eschalier","year":"2013","unstructured":"Eschalier R, McMurray J, Swedberg K, Van Veldhuisen D, Krum H, Pocock SJ, et al. Safety and efficacy of Eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function. J Am Coll Cardiol. 2013;62(17):9.","journal-title":"J Am Coll Cardiol"},{"key":"2439_CR5","unstructured":"National Guideline Centre (Great Britain), National Institute for Health and Care Excellence (Great Britain). Chronic heart failure in adults: diagnosis and management [Internet]. 2018 [cited 2021 Mar 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536075\/"},{"key":"2439_CR6","unstructured":"National Institute for Health and Care Excellence (Great Britain). Acute heart failure: diagnosing and managing acute heart failure in adults. London: National Institute for Health and Care Excellence (NICE); 2014."},{"issue":"8","key":"2439_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. Document Reviewers 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592.","journal-title":"Eur J Heart Fail"},{"key":"2439_CR8","doi-asserted-by":"publisher","unstructured":"WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, et al.. ACC\/AHA\/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation [Internet]. 2016 Sep 27 [cited 2021 Mar 20];134(13). Available from: https:\/\/doi.org\/10.1161\/CIR.0000000000000435","DOI":"10.1161\/CIR.0000000000000435"},{"issue":"8","key":"2439_CR9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2215\/CJN.01150112","volume":"7","author":"PA Sarafidis","year":"2012","unstructured":"Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, et al. Prevalence and factors associated with hyperkalemia in Predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol. 2012 Aug;7(8):1234\u201341. https:\/\/doi.org\/10.2215\/CJN.01150112.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"2439_CR10","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/14656566.2016.1190333","volume":"17","author":"M Epstein","year":"2016","unstructured":"Epstein M, Pitt B. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. Expert Opin Pharmacother. 2016 Jul;17(10):1435\u201348. https:\/\/doi.org\/10.1080\/14656566.2016.1190333.","journal-title":"Expert Opin Pharmacother"},{"key":"2439_CR11","unstructured":"Jenkins R, Mandarano L, Gugathas S, Kaski JC, Anderson L, Banerjee D. Impaired renal function affects clinical outcomes and management of patients with heart failure. ESC Heart Fail.:9."},{"issue":"Suppl 1","key":"2439_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7861\/futurehosp.6-1-s104","volume":"6","author":"R Lowe-Jones","year":"2019","unstructured":"Lowe-Jones R, Junarta J, Salha A, Francheska BK, Anderson L, Kaski JC, et al. The scope of a combined kidney failure-heart failure clinic. Future Healthc J. 2019 Mar;6(Suppl 1):104. https:\/\/doi.org\/10.7861\/futurehosp.6-1-s104.","journal-title":"Future Healthc J"},{"issue":"2","key":"2439_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ki.2014.382","volume":"88","author":"SR Ash","year":"2015","unstructured":"Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015 Aug;88(2):404\u201311. https:\/\/doi.org\/10.1038\/ki.2014.382.","journal-title":"Kidney Int"},{"issue":"3","key":"2439_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015 Jan 15;372(3):222\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1411487.","journal-title":"N Engl J Med"},{"issue":"21","key":"2439_CR15","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014 Dec 3;312(21):2223\u201333. https:\/\/doi.org\/10.1001\/jama.2014.15688.","journal-title":"JAMA."},{"issue":"10","key":"2439_CR16","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F, Pi\u00f1a IL, McCullough PA, Filippatos G, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015 Oct;17(10):1050\u20136. https:\/\/doi.org\/10.1002\/ejhf.300.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2439_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114686","volume":"9","author":"F Stavros","year":"2014","unstructured":"Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014;9(12):e114686. https:\/\/doi.org\/10.1371\/journal.pone.0114686.","journal-title":"PLoS One"},{"issue":"9","key":"2439_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2439_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1161\/CIRCULATIONAHA.117.031717","volume":"137","author":"C deFilippi","year":"2018","unstructured":"deFilippi C, Seliger S. The cardiac troponin renal disease diagnostic conundrum: past, present, and future. Circulation. 2018;137(5):452\u20134. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031717.","journal-title":"Circulation."},{"issue":"3","key":"2439_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.15420\/ecr.2019.28.2","volume":"14","author":"D Banerjee","year":"2019","unstructured":"Banerjee D, Perrett C, Banerjee A. Troponins, acute coronary syndrome and renal disease: from acute kidney injury through end-stage kidney disease. Eur Cardiol Rev. 2019;14(3):187\u201390. https:\/\/doi.org\/10.15420\/ecr.2019.28.2.","journal-title":"Eur Cardiol Rev"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02439-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02439-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02439-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T12:27:35Z","timestamp":1625574455000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02439-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2439"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02439-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has received ethical approval from the Cambridge NHS Research Ethics Committee and is pending approval from the Medicines and Healthcare Regulatory Authority.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no other competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}